Pfizer, Tadworth, UK.
Sarah Dunnett Consulting Ltd, Newbury, UK.
Pharmaceut Med. 2021 May;35(3):147-155. doi: 10.1007/s40290-021-00390-z. Epub 2021 Jul 14.
European pharmaceutical companies have a legal requirement to provide non-promotional Medical Information (MI) services to support healthcare professionals (HCPs) who are using their medicinal products. While the industry has self-regulating bodies with established Codes of Practice, these mainly focus on promotional messaging and commercial activities. In the absence of similar frameworks for MI, such services struggle to understand how to meet HCP digital expectations, often in fear of breaching the promotional codes. This is limiting access to the wealth of non-promotional patient-focussed information held within the industry. Meanwhile, a large volume of unregulated, low-quality information can be readily found on the internet. To understand the current status, the Medical Information Leaders in Europe (MILE) industry association performed a benchmarking survey which explored the online MI service provision of 13 mid-large pharmaceutical companies across Europe. This highlighted a great diversity in approach in terms of geographical coverage and content. Visibility and access for HCPs is complex, compromising online engagement and website utilisation. This MILE position paper highlights the critical need to establish a clear governance model, which empowers pharmaceutical company MI functions to provide unbranded, non-promotional, medicinal product information sources to support HCP online information needs. It is essential to build confidence, transparency and trust by establishing a practical quality framework with principles and standards for online MI services for HCPs.
欧洲制药公司有法律要求提供非促销性质的医学信息 (MI) 服务,以支持使用其药品的医疗保健专业人员 (HCP)。虽然该行业有自我监管机构和既定的行业规范,但这些主要集中在促销信息和商业活动上。由于缺乏类似的 MI 框架,这些服务难以满足 HCP 的数字期望,往往担心违反促销规范。这限制了对行业内丰富的非促销、以患者为中心的信息的获取。与此同时,互联网上也可以轻松找到大量不受监管、低质量的信息。为了了解当前的情况,欧洲医学信息领导者 (MILE) 行业协会进行了基准调查,该调查探讨了欧洲 13 家中型制药公司的在线 MI 服务提供情况。这突出了在地理覆盖范围和内容方面方法的多样性。HCP 的可见性和可访问性很复杂,影响了在线参与度和网站使用率。这份 MILE 立场文件强调了建立明确治理模式的迫切需要,该模式授权制药公司的 MI 部门提供无品牌、非促销性质的药品信息来源,以支持 HCP 的在线信息需求。通过为 HCP 在线 MI 服务建立原则和标准的实用质量框架,建立信心、透明度和信任至关重要。